NCT06698965 - Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 13, 2024

Primary Completion Date

October 31, 2029

Study Completion Date

October 31, 2029

Conditions

Lung Cancer, Small Cell

Interventions

DRUG

Chemotherapy （Etoposide and Carboplatin）

"Etoposide: 80-100mg/m2, Q3W, intravenous infusion is administered on day 1, 2 and 3 of each cycle.~Carboplatin: AUC=5, Q3W, intravenous infusion is administered on day 1 of each cycle."

DRUG

Immunotherapy （Envafolimab）

Envafolimab: 300mg, Q3W, subcutaneous injection is administered on day 1 of each cycle.

DRUG

Trilaciclib

Trilaciclib: 240mg/m2, Q3W, intravenous infusion should be completed within 4 hours before daily chemotherapy

Trial Locations (1)

200030

RECRUITING

Shanghai Chest Hospital, Shanghai